Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NASDAQ | Common Stock
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.
Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.
It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use.
The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use.
It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019.
Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 28, 24 | 0.00 Decreased by -100.00% | 1.36 Decreased by -100.00% |
| Nov 8, 23 | 0.00 Decreased by -100.00% | 1.19 Decreased by -100.00% |
| Aug 8, 23 | 1.20 Increased by +12.15% | 1.03 Increased by +16.50% |
| May 3, 23 | 0.83 Decreased by -38.06% | 1.12 Decreased by -25.89% |
| Mar 1, 23 | 1.21 Decreased by -14.18% | 1.09 Increased by +11.01% |
| Nov 2, 22 | 1.25 Decreased by -28.57% | 1.01 Increased by +23.76% |
| Aug 3, 22 | 1.07 Decreased by -33.95% | 1.34 Decreased by -20.15% |
| May 4, 22 | 1.34 Increased by +4.37 K% | 1.14 Increased by +17.54% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 944.96 M Increased by +7.82% | 127.07 M Increased by +108.40% | Increased by +13.45% Increased by +93.28% |
| Mar 31, 23 | 832.06 M Decreased by -6.01% | 54.68 M Decreased by -73.23% | Increased by +6.57% Decreased by -71.52% |
| Dec 31, 22 | 942.03 M Decreased by -7.14% | 120.41 M Decreased by -30.47% | Increased by +12.78% Decreased by -25.13% |
| Sep 30, 22 | 925.36 M Decreased by -10.77% | 135.84 M Decreased by -58.40% | Increased by +14.68% Decreased by -53.38% |
| Jun 30, 22 | 876.41 M Increased by +5.27% | 60.97 M Decreased by -61.44% | Increased by +6.96% Decreased by -63.37% |
| Mar 31, 22 | 885.25 M Increased by +158.54% | 204.26 M Increased by +265.59% | Increased by +23.07% Increased by +164.05% |
| Dec 31, 21 | 1.01 B Increased by +36.11% | 173.18 M Decreased by -9.12% | Increased by +17.07% Decreased by -33.23% |
| Sep 30, 21 | 1.04 B Increased by +62.94% | 326.54 M Increased by +11.51% | Increased by +31.49% Decreased by -31.56% |